Prospects for disease modification in osteoarthritis

Nature Clinical Practice Rheumatology

Volumn 2, Issue 6, 2006, Pages 304-312

  Abramson, Steven B ^a   Attur, Mukundan ^b   Yazici, Yusuf ^c  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b Department of Medicine   (United States)

^c Department of Medicine   (United States)

Author keywords

Cartilage; DMOADs; Osteoarthritis; Structure modification; Treatment

Indexed keywords

ALENDRONIC ACID; AMG 108; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGENASE 3; DIACETYLRHEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; GLUCOSAMINE SULFATE; HYALURONIC ACID; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; METALLOPROTEINASE INHIBITOR; NITRIC OXIDE; PIOGLITAZONE; PLACEBO; PRALNACASAN; PROSTAGLANDIN E2; RECOMBINANT SOMATOMEDIN C; RISEDRONIC ACID; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BIOMECHANICS; BURSITIS; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TARGETING; DUPUYTREN CONTRACTURE; FROZEN SHOULDER; HEREDITY; HUMAN; JOINT LAXITY; JOINT PROSTHESIS; KNEE OSTEOARTHRITIS; LIVER TOXICITY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NONHUMAN; OBESITY; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

ANTIRHEUMATIC AGENTS; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 33744932949     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0193     Document Type: Review

References (51)

1. Pelletier JP et al. (2001) Osteoarthritis, an inflammatory disease: potential implications for the selection of new therapeutic agents. Arthritis Rheum 44: 1237-1247
2. Wieland HA et al. (2005) Osteoarthritis - an untreatable disease? Nat Rev Drug Discov 4: 331-334
3. Hutchinson JW et al. (1998) Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 80: 907-908
4. Brandt KD et al. (2005) Effects of doxycycline on progression of osteoarthritis: Results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 52: 2015-2025
5. Bettica P et al. (2002) Evidence for increased bone resorption in patients with progressive knee osteoarthritis: Longitudinal results from the Chingford study. Arthritis Rheum 46: 3178-3184
6. Hayami T et al. (2004) The role of subchondral bone remodeling in osteoarthritis: Reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50: 1193-1206
7. Ayral X et al. (2005) Synovitis: A potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 13: 361-367
8. Aigner T et al. (2002) Roles of chondrocytes in the pathogenesis of osteoarthritis. Curr Opin Rheumatol 14: 578-584
9. Glasson SS et al. (2005) Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434: 644-648
10. Attur MG et al. (2000) Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem 275: 40307-40315
11. Smith AJ et al. (2004) Extended haplotypes and linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: Association with knee osteoarthritis. Genes Immun 5: 451-460
12. Caron JP et al. (1996) Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 39: 1535-1544
13. Zhang X et al. (2004) Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res 22: 742-750
14. Fernandes J et al. (1999) In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: Prevention of osteoarthritis progression. Am J Pathol 154: 1159-1169
15. Chevalier X et al. (2005) Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: A multicenter study J Rheumatol 32: 1317-1323
16. Chevalier X et al. (2005) Results from a double blind, placebo-controlled, multicenter trial of a single intra-articular injection of anakinra in patients with osteoarthritis of the knee. Arthritis Rheum 52 (Suppl): S507
17. Economides AN et al. (2003) Cytokine traps: Multicomponent, high-affinity blockers of cytokine action. Nat Med 9: 47-52
18. Rudolphi K et al. (2003) Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 11: 738-746
19. Kobayashi T et al. (2005) Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum 52: 479-487
20. Fukui N et al. (2003) Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am 85-A (Suppl 3): S59-S66
21. Clements KM et al. (2003) Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum 48: 3452-3463
22. Patel IR et al. (1998) TNF-alpha convertase enzyme from human arthritis-affected cartilage: Isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha. J Immunol 160: 4570-4579
23. Kobayashi M et al. (2005) Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 52: 128-135
24. 2, and IL-8. Proc Assoc Am Physicians 110: 65-72
25. Kaneko S et al. (2000) Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 6: 71-79
26. de Hooge AS et al. (2005) Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. Osteoarthritis Cartilage 13: 66-73
27. Merz D et al. (2003) IL-8/CXCL8 and growth-related oncogene alpha/CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol 171: 4406-4415
28. Yasuhara R et al. (2005) Interleukin-1beta induces death in chondrocyte-like ATDC5 cells through mitochondrial dysfunction and energy depletion in a reactive nitrogen and oxygen species-dependent manner. Biochem J 389: 315-323
29. Pelletier J et al. (1999) Reduction in the structural changes of experimental osteoarthritis by a nitric oxide inhibitor. Osteoarthritis Cartilage 7: 416-418
30. van den Berg WB et al. (1999) Animal models of arthritis in NOS2-deficient mice. Osteoarthritis Cartilage 7: 1413-1415
31. Caldwell JR et al. (2000) A safety, tolerability and pharmaco-kinetic study of intra-articular recombinant human insulin-like growth factor 1 (rhIGF-1) in patients with severe osteoarthritis of the knee. Arthritis Rheum 43: S223
32. Haupt JL et al. (2005) Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J Orthop Res 23: 118-126
33. Food and Drug Administration [http://www.fda.gov/cder/guidance/ 2199dft.doc]
34. Dougados M et al. (2001) Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum 44: 2539-2547
35. Pham T et al. (2004) Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis 63: 1611-1617
36. Reginster JY et al. (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet 357: 251-256
37. Pavelka K et al. (2002) Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162: 2113-2123
38. Mazzuca SA et al. (2002) Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 46: 1223-1227
39. Jubb RW et al. (2003) A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract 57: 467-474
40. Spector TD et al. (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: Results of the BRISK randomized, controlled trial. Arthritis Res Ther 7: R625-R633
41. Garnero P et al. (2004) Treatment with risedronate reduced urinary CTX-II, a specific biochemical marker of cartilage type II collagen degradation, in a 24 month study of knee OA. Arthritis Rheum 50 (Suppl): S656
42. Buckland-Wright C et al. (2005) Risedronate protects against subchondral bone loss in OA knee patients with progressive joint space narrowing. Arthritis Rheum 52 (Suppl): S460
43. Carbone LD et al. (2004) The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 50: 3516-3525
44. Amin AR et al. (1996) A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci 93: 14014-14019
45. Yu LP Jr et al. (1992) Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 35: 1150-1159
46. Mazzuca SA et al. (2006) Comparison of quantitative and semi-quantitative indicators of joint space narrowing in subjects with knee osteoarthritis. Ann Rheum Dis 65: 64-68
47. Raynauld JP et al. (2002) Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum 50: 476-487
48. Hunter D et al. (2004) The meniscus and cartilage loss. Arthritis Rheum 50: S141
49. Sharif M et al. (2004) Suggestions of nonlinear or phasic progression of knee ostearthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 50: 2479-2488
50. Garnero P et al. (2005) Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: The ECHODIAH cohort. J Rheumatol 32: 697-703
51. Garnero P et al. (2002) Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46: 2613-2624